Differential expression of ERCC1 in pancreas adenocarcinoma: High tumor expression is associated with earlier recurrence and shortened survival after resection

Annals of Surgical Oncology

Volumn 18, Issue 9, 2011, Pages 2699-2705

  Maithel, Shishir K ^a   Coban, Ipek ^a   Kneuertz, Peter J ^a   Kooby, David A ^a   El Rayes, Bassel F ^a   Kauh, John S ^a   Sarmiento, Juan ^a   Staley III, Charles A ^a   Volkan Adsay, N ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER INVASION; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PANCREATICODUODENECTOMY; PERINEUM; POSTOPERATIVE PERIOD; PROGNOSIS; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; TREATMENT OUTCOME; TUMOR DIFFERENTIATION; TUMOR VOLUME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 80052702914     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-1610-x     Document Type: Article

References (23)

1. R Metzger CG Leichman KD Danenberg, et al. 1998 ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy J Clin Oncol 16 1 309 316 9440758 1:CAS:528:DyaK1cXmsFeruw%3D%3D (Pubitemid 28041614)
2. Y Shirota J Stoehlmacher J Brabender, et al. 2001 ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy J Clin Oncol 19 23 4298 4304 11731512 1:CAS:528:DC%2BD3MXptlGjtLk%3D (Pubitemid 33096777)
3. JH Klinkenbijl J Jeekel T Sahmoud, et al. 1999 Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group Ann Surg 230 6 776 782 10615932 10.1097/00000658-199912000- 00006 1:STN:280:DC%2BD3c%2FotFKkug%3D%3D discussion 782-4. (Pubitemid 30191812)
4. JP Neoptolemos DD Stocken H Friess, et al. 2004 A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer N Engl J Med 350 12 1200 1210 15028824 10.1056/NEJMoa032295 1:CAS:528: DC%2BD2cXit12rtr8%3D (Pubitemid 38339364)
5. HA Burris 3rd MJ Moore J Andersen, et al. 1997 Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 6 2403 2413 9196156 1:CAS:528:DyaK2sXlsFKksLY%3D (Pubitemid 27251144)
6. H Oettle S Post P Neuhaus, et al. 2007 Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial JAMA 297 3 267 277 17227978 10.1001/jama.297.3.267 1:CAS:528:DC%2BD2sXotVCmug%3D%3D (Pubitemid 46143304)
7. G Colucci F Giuliani V Gebbia, et al. 2002 Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale Cancer 94 4 902 910 11920457 10.1002/cncr.10323 1:CAS:528:DC%2BD38XitVKhs74%3D (Pubitemid 34150843)
8. V Heinemann D Quietzsch F Gieseler, et al. 2006 Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer J Clin Oncol 24 24 3946 3952 16921047 10.1200/JCO.2005.05.1490 1:CAS:528:DC%2BD28Xps1Sit78%3D (Pubitemid 46630743)
9. C Louvet R Labianca P Hammel, et al. 2005 Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial J Clin Oncol 23 15 3509 3516 15908661 10.1200/JCO.2005.06.023 1:CAS:528:DC%2BD2MXlsVyhsrg%3D
10. V Heinemann S Boeck A Hinke, et al. 2008 Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer BMC Cancer 8 82 18373843 10.1186/1471-2407-8-82 (Pubitemid 351552578)
11. L Gossage S Madhusudan 2007 Current status of excision repair cross complementing-group 1 (ERCC1) in cancer Cancer Treat Rev 33 6 565 577 17707593 10.1016/j.ctrv.2007.07.001 1:CAS:528:DC%2BD2sXhtVWmtLzJ (Pubitemid 47355341)
12. LP Martin TC Hamilton RJ Schilder 2008 Platinum resistance: the role of DNA repair pathways Clin Cancer Res 14 5 1291 1295 18316546 10.1158/1078-0432. CCR-07-2238 1:CAS:528:DC%2BD1cXislSku7c%3D (Pubitemid 351413906)
13. K Azuma Y Komohara T Sasada, et al. 2007 Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy Cancer Sci 98 9 1336 1343 17640298 10.1111/j.1349-7006.2007.00557.x 1:CAS:528:DC%2BD2sXhtVaksr3F (Pubitemid 47241754)
14. J Bellmunt L Paz-Ares M Cuello, et al. 2007 Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy Ann Oncol 18 3 522 528 17229776 10.1093/annonc/mdl435 1:STN:280:DC%2BD2s7hsFKqtg%3D%3D (Pubitemid 46359633)
15. ZH Huang D Hua X Du, et al. 2008 ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer World J Gastroenterol 14 41 6401 6407 19009659 10.3748/wjg.14.6401 1:CAS:528:DC%2BD1MXis1eltbY%3D
16. H Akita Z Zheng Y Takeda, et al. 2009 Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma Oncogene 28 32 2903 2909 19543324 10.1038/onc.2009.158 1:CAS:528:DC%2BD1MXnsFSit7k%3D
17. A Mancuso S Sacchetta PC Saletti, et al. 2010 Clinical and molecular determinants of survival in pancreatic cancer patients treated with second-line chemotherapy: results of an Italian/Swiss multicenter survey Anticancer Res 30 10 4289 4295 21036754 1:STN:280:DC%2BC3cbjsVGqug%3D%3D
18. A Jemal R Siegel E Ward, et al. 2007 Cancer statistics, 2007 CA Cancer J Clin 57 1 43 66 17237035 10.3322/canjclin.57.1.43 (Pubitemid 46148091)
19. H Kamikozuru H Kuramochi K Hayashi, et al. 2008 ERCC1 codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum-based chemotherapy Int J Oncol 32 5 1091 1096 18425336 1:CAS:528:DC%2BD1cXmtlSntLs%3D
20. KD Steffensen M Waldstrom U Jeppesen, et al. 2008 Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer Int J Gynecol Cancer 18 4 702 710 17961161 10.1111/j.1525-1438.2007. 01068.x 1:STN:280:DC%2BD1crisl2ltQ%3D%3D (Pubitemid 352020157)
21. JJ Yu C Mu KB Lee, et al. 1997 A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues Mutat Res 382 1-2 13 20 9360634 1:CAS:528:DyaK2sXnt1yhsrg%3D (Pubitemid 28376643)
22. M Monzo I Moreno A Navarro, et al. 2007 Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine Oncology 72 5-6 364 370 18204222 10.1159/000113534 1:CAS:528: DC%2BD1cXhs1yitrs%3D (Pubitemid 351238151)
23. J Stoehlmacher DJ Park W Zhang, et al. 2004 A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer Br J Cancer 91 2 344 354 15213713 1:CAS:528:DC%2BD2cXls1eht7o%3D (Pubitemid 39037082)